Arecor Therapeutics (LON:AREC) Posts Quarterly Earnings Results

Arecor Therapeutics (LON:AREC) issued its quarterly earnings data on Thursday. The company reported GBX (8) earnings per share for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a return on equity of 14.26% and a net margin of 38.74%.

Arecor Therapeutics Stock Down 3.0%

Shares of LON AREC traded down GBX 2.19 during trading hours on Friday, hitting GBX 70.31. 46,696 shares of the stock were exchanged, compared to its average volume of 24,785. The company has a market cap of £26.55 million, a PE ratio of 35.16 and a beta of -0.18. Arecor Therapeutics has a 12 month low of GBX 56 and a 12 month high of GBX 95. The company has a quick ratio of 6.24, a current ratio of 4.35 and a debt-to-equity ratio of 1.52. The firm has a fifty day moving average price of GBX 71.73 and a 200-day moving average price of GBX 67.95.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.